CPhI Online

- Digitisation

TraceLink announces results from FDA DSCSA Pilot Program

23 Jun 2020

Key findings demonstrate the value of network solutions to secure and digitalize the pharmaceutical supply chain.

TraceLink, a digital platform company for the life science supply chain, has announced results from its pilot for the FDA Pilot Project Program under the Drug Supply Chain Security Act (DSCSA).

The TraceLink pilot focused on two workstreams: digital recalls across a supply network; and an interoperable blockchain network solution. The pilots included 22 participating companies from pharmaceutical manufacturers, wholesale distributors, third-party logistic providers, hospitals and retail pharmacies.

The pilot employed early-stage technology solutions to address pharmaceutical supply chain challenges and establish a deep understanding of how technology can realistically ease those burdens. Both workstreams were designed to create a vision and blueprint for the data, operational processes, business systems, and network connections required to realize DSCSA 2023 compliance and to digitalize pharmaceutical drug recalls.

“The results from our pilot gleaned significant insights that will help solve different, but equally important, challenges that the pharmaceutical industry will continue to face until DSCSA 2023, with both workstreams highlighting the value of a digital network in improving processes and efficiencies within the supply chain,” said Shabbir Dahod, president and CEO of TraceLink. Dahod advised that now is the time for the industry to begin acting on some of these pilot findings, including improving processes and allowing better visibility, agility, and collaboration among supply chain stakeholders.”

Product Recalls Workstream: Digital Recalls Across the Supply Network

Pilot participants in TraceLink’s digital recalls workstream explored ways to solve challenges associated with today’s product recall process, plagued by disjointed systems, manual processes, and long delays in communication between supply chain stakeholders including leveraging TraceLink’s emerging digital recalls network solution.

Joe Maki, pilot participant and senior director of pharmacy operations, Novant Health noted that this workstream further demonstrated how inefficient the current industry process is in executing product recalls. “The learnings emphasized how a digital recalls platform could vastly improve the execution of recalls by eliminating manual, error-prone processes and would also help to better define accountability among supply chain stakeholders with improved collaboration­­­­­­­, ultimately reducing the risk to patients by getting recalled product off the market faster.”

The recalls workstream identified a strong opportunity to improve the drug recalls process with the integration of bi-directional communications and digital recall notifications to bolster response times across the execution phase, which would require a collaborative effort among industry stakeholders to create an effective blueprint and roadmap for adoption.

2023 Traceability Workstream, TraceLink’s Interoperable Blockchain Network Solution with Trace Histories

By 2023, DSCSA will require an electronic, interoperable system by 2023 to identify and trace certain prescription drugs. TraceLink’s blockchain workstream evaluated existing information, processes and systems to determine if and how they can meet 2023 DSCSA requirements.

Pilot members analysed the strengths and weaknesses of proposed electronic network models for DSCSA 2023, including the evaluation of TraceLink’s interoperable blockchain solution to determine whether blockchain-centric and/or non-blockchain approaches may be effective.

Business processes related to product traceability are extremely complex due to the diversity of the pharmaceutical supply chain. The findings identified blockchain as one piece of a larger technology solution that could support product traceability under the DSCSA 2023 guidelines. However, the pilot strongly indicates that reliance on any single technology or sole platform to meet the DSCSA 2023 guidelines is extremely unlikely.

Read More

Related Content